Method for simultaneously representing protein disulfide bond and sequence information on line

Through the HCD mode combined with online partial reduction method, the simultaneous characterization of disulfide bonds and sequence information of protein samples is achieved, which solves the problem that is difficult to characterize simultaneously in the prior art, improves the analysis efficiency and reproducibility, and is suitable for antibody drugs quality control.

CN119023828APending Publication Date: 2024-11-26SHANGHAI INST OF PHARMA IND CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310611410.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-26
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The prior art cannot simultaneously characterize the disulfide bond and sequence information of proteins, resulting in low efficiency in quality monitoring and structural analysis of antibody drugs, and the pre-processing steps are cumbersome and time-consuming.

Method used

The HCD mode combined with the online partial reduction method is used to achieve simultaneous characterization of disulfide bonds and sequence information of protein samples through one sample pretreatment and injection analysis, simplifying the pretreatment steps, reducing the consumption of samples and mobile phases, and improving analysis efficiency.

Benefits of technology

High sensitivity and high throughput protein structure characterization is achieved, shortening processing and analysis time, improving the reproducibility and versatility of the method, and is suitable for quality control and structural characterization of antibody drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004254918860000081
    Figure BDA0004254918860000081
  • Figure BDA0004254918860000082
    Figure BDA0004254918860000082
  • Figure BDA0004254918860000091
    Figure BDA0004254918860000091
Patent Text Reader

Abstract

The invention discloses a method for simultaneously representing protein disulfide bond and sequence information on line, which is characterized in that a protein sample and a reducing reagent are subjected to partial reduction reaction through an on-line derivation system on the basis of an HCD mode and then are analyzed. The method provided by the invention has high sensitivity and high throughput, can be applied to quality control of antibody drugs, and can utilize online software to carry out a partial reduction method, so that disulfide bond and sequence information can be simultaneously represented in a map obtained after one-time sample introduction.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of bioengineering, and in particular to a method for simultaneously characterizing protein disulfide bonds and sequence information online. Background Art

[0002] Disulfide bonds (SS bonds) are post-translational modifications formed between sulfur atoms of two cysteine ​​(Cys) groups during the biosynthesis of proteins in cells, which are crucial to protein structure, stability and biological function (Woycechowsky K J, Raines R T. Native disulfide bond formation in proteins [J]. Current opinion in chemical biology, 2000, 4 (5): 533-539.). Monoclonal antibody drugs (mAb) are highly disulfide-bonded recombinant proteins. In theory, each subtype has a clear disulfide bond structure. Non-natural disulfide bond pairing affects the stability, potential efficacy or biological function of biotherapeutic drugs, so disulfide bonds and cysteine-related variants have also become the focus of antibody drug quality monitoring (Kleinberg A, Joseph R, Mao Y, et al. Ultrasensitive disulfides crambling analysis of mAbs by LC-MS with post-column reduction and glycine signal enhancement [J]. Analytical Biochemistry, 2022: 114773.). The amino acid sequence determines the primary structure, and different sequences have their own specific fingerprints.

[0003] The reported method for characterizing antibody disulfide bonds is enzymatic hydrolysis followed by denaturation, where the sample is divided into two parts: one part is injected directly, and the other part is reduced and alkylated before analysis (Lv Fenghua, Huan Minxia, ​​Liu Zhouyang, Tan Qingqiao. IgG2 monoclonal antibody disulfide bond pairing analysis method [P]. Shanghai: CN106153746B, 2020-11-06.).

[0004] Amino acid sequence characterization usually includes three strategies: top-down, middle-down and bottom-up. Hunt et al. used electron transfer fragmentation (ETD) fragmentation mode to characterize the monoclonal antibody sequence and post-translational modifications from the middle-down and bottom-up levels, with a sequence coverage of 95%. The localization analysis of disulfide bonds was performed by combining ETD and ion-ion proton transfer chemistry (IIPC) (Hunt Donald F., Wang Weihan, Zhang Lichao. Compositions and methods for analysis of proteins sequences and post-translational modifications [P].: US10281473, 2019-05-07.).

[0005] Among them, the bottom-up peptide map method is more universal, and its pre-treatment includes denaturation, reduction, alkylation, replacement of buffer solution and then enzymatic hydrolysis, and LC-MS analysis after quenching. The main difference from disulfide bond analysis is the reduction step. HCD is a high-energy collision cleavage method, which belongs to a mode of mass spectrometry fragmentation target ions. HCD can be used to perform secondary fragmentation of the parent ion of the mass spectrometer to produce smaller daughter ions, thereby performing mass-to-nuclear ratio attribution analysis. And the site of HCD mode cleavage is the amide bond, which produces b and y ions and does not break the SS bond. Because HCD cannot fragment disulfide bonds, peptide maps and disulfide bond samples need to be pre-treated separately and then sampled and analyzed separately. At present, there is no method to simultaneously characterize the dual information of disulfide bonds and sequences. Summary of the invention

[0006] In order to solve the defect of the prior art that there is a lack of methods for simultaneously characterizing disulfide bonds and sequence information, the present invention provides a method for simultaneously characterizing protein disulfide bonds and sequence information online. The structural characterization method with both high sensitivity and high throughput developed by the present invention is applied to the quality control of proteins such as antibody drugs. The online partial reduction method can simultaneously characterize disulfide bonds and sequence information in the spectrum after one injection.

[0007] The inventors found that by comparing HCD with the ETD (electron transfer fragmentation) mode (producing c and z ions, which can fragment SS bonds), the secondary fragments generated by the HCD mode of the sample after online partial reduction, ETD and other combined fragmentation techniques can all achieve the detection of disulfide bonds, and HCD can provide more sequence fragment information. However, existing studies have used TCEP to completely reduce the protein amino acid sequence and perform secondary mass spectrometry in the HCD mode, which cannot characterize the information of disulfide bonds. The present invention uniquely uses TCEP reagent to partially reduce disulfide bond-containing peptides, and its product contains both free peptides after reduction and peptides connected by unreduced disulfide bonds. Through the optimization of pretreatment, the partial reduction method can achieve comprehensive characterization of the primary structure in the mass spectrometry HCD mode.

[0008] Specifically, the present invention, based on the HCD mode, only needs to prepare the protein sample to be tested, such as a monoclonal antibody sample (monoclonal antibody includes complete type and Fab fragment type) through one sample pretreatment, and then the sequence information and disulfide bond connection relationship (including unpaired free cysteine) can be simultaneously characterized by one-shot injection LC-MS / MS analysis, without the need to use ETD and other fragmentation modes, and the method has high versatility and universality. An efficient reducing agent is the basis for realizing semi-automatic reduction treatment, and partial reduction can reduce two pretreatments and injection processes to one preparation and injection analysis, which is simple to operate, reduces processing and collection time and sample usage; at the same time, it ensures the repeatability between batches, reduces accidental errors and uncontrollable factors to a certain extent, improves the reproducibility of methods and results, and accelerates the optimization of early methods and the efficiency of antibody drug structure characterization to shorten the research and development and production cycle.

[0009] The present invention aims to solve the time-consuming and labor-intensive problem of the prior art that multiple pretreatment and injection steps are required. The method adopts an online processing method to shorten the processing and analysis time. The pretreatment operation is simple, the derivatization reaction is automated, and the uncontrollable factors introduced by humans are reduced. The method is reliable and stable, and provides a reference for high-throughput antibody structure characterization. Compared with the prior art, the method of the present invention has the following advantages: 1. High-throughput characterization: it can reduce the pretreatment steps, reduce the consumption of samples and mobile phases, shorten the liquid phase mass spectrometry detection time, facilitate the early research and development of samples, and can quickly obtain multiple information; 2. Semi-automatic pretreatment: the online mode makes the method highly repeatable, and the online reduction step can also realize real-time monitoring of the enzymatic efficiency of the sample.

[0010] In order to solve the above technical problems, the first aspect of the present invention provides a method for online simultaneous characterization of protein disulfide bonds and sequence information, which is based on the HCD mode, through an online derivatization system, and the protein sample is subjected to partial reduction reaction with a reducing agent and then analyzed.

[0011] In certain embodiments, the method satisfies one or more of the following conditions:

[0012] The online derivatization system uses a liquid phase autosampler, such as a U3000 liquid phase autosampler. For example, the protein sample can be placed in Reagent A or Reagent B, and the reducing reagent can be placed in Reagent A or Reagent B.

[0013] The protein is an antibody, preferably a monoclonal antibody, for example, a complete monoclonal antibody or a Fab fragment monoclonal antibody.

[0014] The reducing agent is DTT or TCEP.

[0015] Preferably, the monoclonal antibody is bevacizumab or ranibizumab.

[0016] Since the disulfide bonds can be detected by the secondary fragments generated by the HCD mode in the sample after online partial reduction, the technical solution provided by the present invention can detect other proteins in addition to monoclonal antibodies, as long as they are rich in disulfide bonds.

[0017] More preferably, the sample suction speed of the online derivatization system is 0.2-5 μL / s, and / or the mixing times are 2-10 times, such as 3, 4, 5, 7, 9 times, preferably 4 times.

[0018] When the sample volume is 10 μL, the sample speed is 1 to 5 μL / s.

[0019] When the sample aspirate volume is 2 μL, the sample aspirate speed is 0.2 to 1 μL / s.

[0020] In certain embodiments, the method comprises the following steps: one or more of protein denaturation, replacement of buffer solution, enzymatic hydrolysis, injection, detection and data analysis. Preferably, the protein denaturation also includes alkylation.

[0021] In certain embodiments, the enzymolysis comprises a single enzyme enzymolysis or a multi-enzyme enzymolysis. Preferably, the single enzyme is trypsin, and / or, the multi-enzyme enzymolysis is a double enzyme enzymolysis. More preferably, the double enzyme enzymolysis is trypsin and V8 protease, or, trypsin and chymotrypsin.

[0022] In certain embodiments, the final concentration of the reducing agent is 1-100 mM, preferably 2.5-50 mM, more preferably 2.5-40 mM, and even more preferably 20 mM.

[0023] In certain embodiments, the reaction time of the reducing agent is 1 to 30 minutes, preferably 3 to 10 minutes, and more preferably 5 minutes.

[0024] In certain embodiments, the protein denaturation uses a protein denaturing agent such as urea or guanidine hydrochloride, and the alkylation uses a blocking agent that can block the end of a free thiol group, wherein the blocking agent is a reversible thiol modification agent or an irreversible thiol modification agent.

[0025] The blocking agent is iodoacetamide (IAM), N-ethylmaleimide (NEM) or iodoacetic acid (IAA). Preferably, the final concentration of the protein denaturing agent is 1 to 25 M, and / or

[0026] The final concentration of the blocking reagent is 1-1000 mM.

[0027] More preferably, the working concentration of the protein denaturing agent is 5 to 15 M.

[0028] The final concentration of the blocking reagent is 10-100 mM.

[0029] Further more preferably, the working concentration of the protein denaturing agent is 6 to 8 M,

[0030] The final concentration of the blocking reagent was 25 mM.

[0031] In certain embodiments, the replacement buffer solution uses Tris buffer or NH 4 HCO 3 Buffer. Preferably, the working concentration of the replacement buffer is 10 to 200 mM. More preferably, the working concentration of the replacement buffer is 25 to 100 mM. Even more preferably, the working concentration of the replacement buffer is 50 mM.

[0032] In certain embodiments, the detection is performed using LC-ESI-Q Exactive HF-X MS. Preferably, the detection uses gradient elution, and the phase A and phase B used in the gradient elution are 0.05-0.2% formic acid and 0.05-0.2% formic acid acetonitrile, respectively.

[0033] More preferably, the flow rate of the gradient elution is 0.1 to 1 mL / min, and / or,

[0034] The conditions of the gradient elution are: 2% B phase 0.5-1.5 mL, 2-38% B phase 20-30 mL, 38-90% B phase 0.75-2 mL, 90% B phase 0.75-2 mL, 90%-1% B phase 0.25-1 mL, 2% B phase 0.5-1.5 mL.

[0035] In certain embodiments, the phase A and phase B used in the gradient elution are 0.1% formic acid and 0.1% formic acid acetonitrile, respectively.

[0036] The flow rate of the gradient elution is 0.25 mL / min;

[0037] The conditions of the gradient elution are: 2% B phase 0.75 mL, 2-38% B phase 24.25 mL, 38-90% B phase 1.25 mL, 90% B phase 1.25 mL, 90%-1% B phase 0.25 mL, 2% B phase 1 mL.

[0038] In certain embodiments, the data analysis uses BioPharma Finder 4.0.

[0039] Preferably, the data analysis satisfies one or more of the following conditions:

[0040] The maximum quality of the processing parameters of the analysis is 1000-10000,

[0041] The minimum confidence level of the analysis is 50%-100%,

[0042] The signal threshold of the analysis is 1.00E4-1.00E6,

[0043] The mass accuracy of the analysis was ±1-50 ppm.

[0044] More preferably, the maximum mass is 2000-8000,

[0045] The minimum confidence level is 70%-90%,

[0046] The signal threshold is 1.00E5-9.00E5,

[0047] The mass accuracy is ±1-10 ppm.

[0048] Further more preferably, the maximum mass is 4000,

[0049] The minimum confidence level is 80%,

[0050] The signal threshold is 4.00E5,

[0051] The mass accuracy was ±5 ppm.

[0052] On the basis of being in accordance with the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.

[0053] The reagents and raw materials used in the present invention are commercially available.

[0054] The positive progress effect of the present invention is that: compared with the traditional method, this method is based on LC-MS / MS under HCD mode. After preparing the sample to be tested through a sample pretreatment, the sequence information and the disulfide bond connection relationship can be simultaneously characterized by one-shot injection analysis. First, the online method is easy to operate for method optimization and sample determination. Automatic sampling and derivatization can be achieved by writing the conditions required for reduction into the program, which is suitable for high-throughput sample detection and the early method development stage; repeatability tests show that the repeatability of the online program is significantly better than the offline reduction method, reducing the interference of human factors; in addition, antibody drugs often have a small sample volume and are expensive, and the online reduction program can reduce the sample dosage to a certain extent. Second, the partial reduction method shortens the processing and analysis time, and can simultaneously achieve a comprehensive characterization of the primary structure in one-shot injection, including sequence information and disulfide bonds (and free cysteine); third, the HCD mode is more commonly used in mass spectrometry, and the instrument requirements are not high, so the method has versatility and universality. BRIEF DESCRIPTION OF THE DRAWINGS

[0055] Figure 1 This is a mirror image comparison of ranibizumab TIC after digestion with trypsin (Trypsin) and V8 protease (Glu-C) ( Figure 1 A is after reduction, Figure 1 B is before reduction).

[0056] Figure 2 This is the TIC sequence matching diagram of ranibizumab after digestion with trypsin and V8 protease.

[0057] Figure 3 Schematic diagram of the peptide matching results of ranibizumab after trypsin and V8 protease digestion.

[0058] Figure 4 Schematic diagram of the peptide matching results of ranibizumab after trypsin and chymotrypsin digestion.

[0059] Figure 5 This is the TIC sequence matching diagram of bevacizumab after digestion with trypsin and V8 protease.

[0060] Figure 6 Schematic diagram of the bevacizumab peptide matching results after trypsin and V8 protease digestion.

[0061] Figure 7 is the peak area of ​​free peptide at different reaction concentrations.

[0062] Figure 8 is the peak area of ​​disulfide bond peptide fragments at different reaction concentrations.

[0063] Fig. 9 is the reduction rate at different reaction concentrations.

[0064] Fig.10 is the peak area of ​​free peptide at different reaction times.

[0065] Fig.11 is the peak area of ​​disulfide bond peptide at different reaction times.

[0066] Fig.12 is the reduction rate at different reaction times.

[0067] Fig.13 is the disulfide bond and sequence information of ranibizumab; wherein, C represents cysteine, two C The line segments between represent disulfide bonds.

[0068] Fig.14 is the disulfide bond and sequence information of bevacizumab; wherein, C represents cysteine, two C The line segments between represent disulfide bonds.

[0069] Fig.15 Schematic diagram of the pre-processing process.

[0070] Fig.16 Schematic diagram of online reduction derivatization reaction. DETAILED DESCRIPTION

[0071] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.

[0072] Instruments: Ultimate 3000 liquid chromatograph (Thermo Fisher Scientific); Orbitrap HF-X high-resolution mass spectrometer (Thermo Fisher Scientific); Integral 10 water purifier (Millipore); THZ-C constant temperature oscillator (Suzhou Peiying Experimental Equipment Co., Ltd.); KQ-500DE ultrasonic cleaner (Kunshan Ultrasonic Instrument Co., Ltd.); XW-80A vortex mixer (Haimen Qilin Bell Instrument Manufacturing Co., Ltd.); 10k ultrafiltration tube (Millipore, batch number 0000182614); H1650 centrifuge (Hunan Xiangyi Laboratory Instrument Development Co., Ltd.).

[0073] Reagents: acetonitrile (LC grade, Supelco, batch number: l1166230132); formic acid (LC-MS grade, Thermo Fisher Scientific, batch number: 220622); purified water (Milli-Q); ammonium bicarbonate (99.5%, Sigma, batch number: P2286969); tris(2-carboxyethyl)phosphine (TCEP) (98%, Sigma, batch number: P2287041); trypsin (Trypsin) (sequencing grade, Promega, batch number: 0000517254); V8 protease (Glu-C) (sequencing grade, Sigma, batch number: 11420399001); iodoacetamide (IAM) (≥99%, Sigma, batch number: SLCL4705); urea (99.5%, aladdin, batch number: L2114239).

[0074] The program of the automatic sample injector of the online software used in the present invention is:

[0075] UdpDraw Reagent A Vial, 10μL, 2μL / s (sample volume)

[0076] UdpDraw Reagent B Vial, 2μL, 0.4μL / s

[0077] UdpDraw Air, 12μL, 2μL / s

[0078] UdpMove Syring Unload 12μL, Global Speed

[0079] UdpMove Syring load 12μL, Global Speed

[0080] UdpMove Syring Unload 12μL, Global Speed

[0081] UdpMove Syring load 12μL, Global Speed

[0082] UdpMove Syring Unload 12μL, Global Speed

[0083] UdpMove Syring load 12μL, Global Speed

[0084] UdpMove Syring Unload 12μL, Global Speed

[0085] UdpMix needle wash 100μL

[0086] UdpMix wait 300s (restore time)

[0087] UdpInject Marker

[0088] UdpInject Valve Inject

[0089] UdpInject Valve Waste

[0090] UdpMoveSyringeHome Global Speed

[0091] UdpDraw Wash, 100 μL

[0092] UdpDispense Drain, 100 μL.

[0093] The schematic diagram of the pre-processing process is as follows: Fig.15 shown.

[0094] The schematic diagram of the online reduction derivatization reaction is as follows Fig.16 shown.

[0095] Example 1

[0096] 1.1 Basic steps:

[0097] Step 1) Denaturation and alkylation: Take 10 μL (about 100 μg) of ranibizumab (Dominer, batch number 20211112) sample in an EP tube, add 75 μL of 8M urea solution to a final concentration of about 6M, 5 μL of 0.5M iodoacetamide (IAM) solution to a final concentration of 25 mM, add water to a total volume of 100 μL, and the final concentration of the sample is about 1 μg / μL. Vortex to mix, and shake at 36°C for 2h.

[0098] Step 2) Replace the buffer solution: add 400 μL of deionized water to a Millipore ultrafiltration tube (10k), centrifuge at 14000 g for 10 min, repeat once. Add the reaction solution to the ultrafiltration tube, add 300 μL of 50 mM NH 4 HCO 3 (pH 6.7), centrifuge at 14000g for 10 min, repeat once. Centrifuge at 14000g for 5 min to concentrate. Centrifuge at 1000g for 2 min, add 50 mM NH 4 HCO 3 Bring the total volume to 100 μL.

[0099] Step 3) Enzymatic hydrolysis: Enzymatic hydrolysis method: Trypsin single enzyme hydrolysis: Add trypsin at a 1:50 enzyme (trypsin) substrate mass ratio and shake at 37°C for 4 hours. Add V8 protease at a 1:20 enzyme (V8 protease) substrate ratio and shake overnight. Terminate the reaction with 1% formic acid.

[0100] Step 4) Injection: The ranibizumab sample was placed in Reagent A and the reducing reagent TCEP was placed in Reagent B through the U3000 liquid phase autosampler online derivatization system, and a partial reduction derivatization reaction was performed according to the procedure. After comparing the reaction concentration and time by the method, the pH of the reducing reagent TCEP was 6.5, the final concentrations of TCEP were 0, 2.5, 5, 10, 20, and 40 mM, and the reaction times were 0, 3, 5, and 8 min, respectively (the final concentration and the reaction time were both single factors, and the specific results are shown in Figure 7-12 ).

[0101] Step 5) Detection: LC-ESI-QE HF-X MS was used for separation and analysis. Chromatographic conditions: chromatographic column Acclaim120C18 (2.1*150, 3μm); phase A was 0.1% formic acid water, phase B was 0.1% formic acid acetonitrile; gradient elution (0.0-3.0min, B2%; 3.0-100.0min, B2%-38%; 100.0-105.0min, B38%-90%; 105.0-110.0min, B90%; 110.0-111min, B90%-1%; 111-115min, B2%); flow rate 0.25mL / min; column temperature 50°C; injection volume 10μL. Mass spectrometry conditions: resolution: 60000 / 15000; NCE: 27.

[0102] Step 6) The disulfide bond and peptide map data were analyzed and screened using BioPharma Finder 5.0 data processing software (Thermo Fisher Scientific), with a maximum mass of 7000, a minimum confidence of 80%, a signal threshold of 4.00E5, and a mass accuracy of 10 ppm.

[0103] Result: Mirror Figure 1 The TIC difference before and after reduction was compared. To avoid the influence of TCEP addition on the comparison effect, the total ion chromatogram (TIC) from 3 to 115 min was intercepted and the mirror image was used. Figure 1 A is the spectrum after TCEP reduction, Figure 1 B is the unreduced spectrum. The results show that Figure 1 The disulfide peptide peak in B is obviously larger than the peak after reduction. Figure 1 The corresponding reduced free peptides can also be found in A. The specific information of the five pairs of disulfide bonds identified under this condition is shown in Table 1. After sequence matching of the reduced spectrum, after condition screening, the coverage of both light and heavy chains can reach 100%. Figure 3 The peak time of each peptide detected in Figure 2 In addition, the b and y ion fragments of the N-terminal and C-terminal characteristic peptides were analyzed as shown in Table 2-5.

[0104] Table 1 Disulfide bond matching results of ranibizumab after trypsin and V8 protease digestion. Disulfide bond peptide peak areas at different reaction concentrations.

[0105]

[0106] Table 2 LC-N-terminal sequence: DIQLTQSPSSLSASVGDR (SEQ ID NO: 44) matching results.

[0107]

[0108] Table 3 LC-C-terminal sequence: SFNRGEC (SEQ ID NO: 45) matching results.

[0109]

[0110] Table 4 HC-N terminal sequence: EVQLVESGGGLVQPGGSLR (SEQ ID NO: 46) matching results

[0111]

[0112] Table 5 HC-C terminal sequence: SCDKTHL (SEQ ID NO: 47) matching results.

[0113]

[0114]

[0115] Take the peptide segment 1:S127-R142 / 1:V191-K207 connected by 1:C134 / 1:C194 in Table 1 as an example. Taking the TCEP reaction concentration as a single variable factor, the reaction conditions when the final TCEP concentration was 0, 2.5, 5, 10, 20, and 40 mM were investigated. As the TCEP concentration increased, the peak area corresponding to the complete peptide chain connected by disulfide bonds showed a downward trend ( Figure 8 ), while the free peptide chain peak area showed an overall upward trend ( Figure 7). By calculating the reduction rate = (initial unreduced disulfide bond peptide peak area - partially reduced disulfide bond peptide peak area) / initial unreduced disulfide bond peptide peak area * 100%, the relationship curve between TCEP concentration and reduction rate was fitted, see Fig. 9 Considering that the reduction rate reached about 50%, the final reaction concentration was 20mM. Taking the TCEP reaction time as the single variable factor, the reduction conditions at 0, 3, 5, and 8min reaction times were investigated. Figure 10-12 As the reaction time increased, the reduction rate gradually increased. When the reaction time exceeded 3 min, it gradually leveled off. Considering the durability and efficiency of the method, a reaction time of 5 min was finally selected, which not only achieved faster online derivatization but also obtained stronger signal response values ​​(the peak areas of each signal were greater than 1E7). Figure 3 The summary table of the peptide map sequence coverage of ranibizumab after enzymatic digestion is shown in Table 6.

[0116] Table 6 Summary of peptide map sequence coverage of ranibizumab after trypsin and V8 protease digestion

[0117] Attribution Number of mass peaks detected Mass spectrum peak area Sequence coverage Abundance 1: Light chain 151 20.3% 100.0% 30.58% 2: Heavy chain 318 79.7% 100.0% 69.42%

[0118] The addition of alkylating agents can not only identify free cysteine, but also reduce the probability of mispaired disulfide bonds artificially introduced during the operation, as shown in Table 7.

[0119] Table 7 Effects of alkylating agents on mismatched disulfide bonds.

[0120]

[0121] The sequence information and disulfide bond positions of SEQ ID NO:48 and SEQ ID NO:49 are as follows: Fig.13 shown.

[0122] 1.2 Effects of different enzyme types

[0123] Steps 1) to 2) are the same as steps 1) to 2) of 1.1.

[0124] Step 3) Enzymatic hydrolysis:

[0125] Enzymatic hydrolysis method 1: Single enzyme hydrolysis, i.e. trypsin: enzyme (Trypsin) substrate mass ratio of 1:50, add enzyme and shake at 37°C overnight.

[0126] Enzymatic hydrolysis method 2: Double enzyme hydrolysis, i.e. trypsin and V8 protease (Glu-C): add enzyme at a 1:50 enzyme (Trypsin) substrate mass ratio and shake at 37°C for 4 hours. Add V8 protease (Glu-C) at a 1:20 enzyme substrate ratio and shake overnight. Terminate the reaction with 1% formic acid.

[0127] Enzymatic hydrolysis method 3: Double enzyme hydrolysis, i.e. trypsin and chymotrypsin (Chymo): add enzyme at a 1:50 enzyme (Trypsin) substrate mass ratio and shake at 37°C for 4 hours. Add chymotrypsin at a 1:20 (enzyme: substrate, W / W) ratio and shake at 37°C overnight.

[0128] Steps 4) to 6) are the same as steps 4) to 6) of 1.1.

[0129] Results: Table 8 compares the effects of different enzyme types and finds that multiple enzyme combinations (double enzyme digestion) can produce more sufficient enzymatic peptides than single enzyme digestion, and the peptides produced by digestion are of moderate length with no missing fragments. With the same processing and analysis process, the LC coverage of the peptide map made by digestion method 3 was 90.2%, with four short peptide chains lost; the HC coverage was 97.8%, with two short peptide chains lost. The sequence coverage of digestion method 2 can reach 100% based on the identification of all disulfide bonds. The schematic diagram of the peptide matching results of ranibizumab after trypsin and chymotrypsin digestion is shown in Figure 4 . Figure 4 The summary table of the peptide map sequence coverage of ranibizumab after enzymatic digestion is shown in Table 9.

[0130] Table 8 Effect of different enzyme types on the number of peptides detected.

[0131] Trypsin Trypsin and V8 protease Trypsin and chymotrypsin Number of peptides detected by LC 106 151 127 Number of peptides detected by HC 197 318 199

[0132] Table 9 Summary of peptide map sequence coverage of ranibizumab after trypsin and chymotrypsin digestion

[0133] Attribution Number of mass peaks detected Mass spectrum peak area Sequence coverage Abundance 1: Light chain 129 25.7% 90.2% 30.25% 2: Heavy chain 199 74.3% 97.8% 69.75%

[0134] 1.3 Effect of different reducing agents

[0135] Steps 1) to 3) are the same as steps 1) to 3) of 1.1.

[0136] Step 4): Injection: Place the ranibizumab sample in Reagent A and the reducing reagent DTT in Reagent B using the U3000 liquid phase autosampler online derivatization system, and perform partial reduction derivatization reaction according to the procedure. After comparing the reaction concentration and time by the method, the pH of the reducing reagent DTT is 6.5, the final concentration of DTT is 20 mM, and the reaction time is 30 min.

[0137] Step 5) to step 6) are the same as steps 5) to 6) of 1.1.

[0138] Results: When the reducing agent was DTT, the effect of using DTT for 30 min was similar to that of using TCEP for 10 min.

[0139] Example 2

[0140] Basic steps

[0141] Step 1) Denaturation and alkylation: Take 100 μg of bevacizumab sample (Roche, batch number H0355) in an EP tube, add 75 μL of 8M urea solution to a final concentration of about 6M, 5 μL of 0.5M iodoacetamide (IAM) solution to a final concentration of 25 mM, add water to a total volume of 100 μL, and the final concentration of the sample is about 1 μg / μL. Vortex and shake at 36°C for 2h.

[0142] Step 2) Replace the buffer solution: add 400 μL of deionized water to a Millipore ultrafiltration tube (10k), centrifuge at 14000 g for 10 min, repeat once. Add the reaction solution to the ultrafiltration tube, add 300 μL of 50 mM NH 4 HCO 3 (pH 6.7), 14000g for 10 min, repeat once. Centrifuge at 14000g for 5 min to concentrate. Inverted centrifuge at 1000g for 2 min, add 50 mM NH 4 HCO 3 The total volume was approximately 100 μL.

[0143] Step 3) Enzymatic hydrolysis: Double enzyme hydrolysis with trypsin and V8 protease (Glu-C): Trypsin was added at a 1:50 enzyme (trypsin) substrate mass ratio and shaken at 37°C for 4 hours. V8 protease was added at a 1:20 enzyme (V8 protease) substrate ratio and shaken overnight. The reaction was terminated with 1% formic acid.

[0144] Step 4) Injection: The bevacizumab sample was placed in Reagent A and the reducing reagent TCEP was placed in Reagent B using the U3000 liquid phase autosampler online derivatization system. A partial reduction derivatization reaction was performed according to the procedure. After comparing the reaction concentration and time by the method, the reducing reagent TCEP pH was 6.5, the reaction concentration was 20 mM, and the reaction time was 300 s.

[0145] Step 5) Detection: LC-ESI-QE HF-X MS was used for separation and analysis. Chromatographic conditions: chromatographic column Acclaim120C18 (2.1*150, 3μm); phase A was 0.1% formic acid water, phase B was 0.1% formic acid acetonitrile; gradient elution (0.0-3.0min, B2%; 3.0-100.0min, B2%-38%; 100.0-105.0min, B38%-90%; 105.0-110.0min, B90%; 110.0-111min, B90%-1%; 111-115min, B2%); flow rate 0.25mL / min; column temperature 50°C; injection volume 10μL. Mass spectrometry conditions: resolution: 60000 / 15000; NCE: 27.

[0146] Step 6) Use BioPharma Finder 5.0 data processing software (Thermo Fisher Scientific) to perform deconvolution analysis on the disulfide bond and peptide map data.

[0147] Results: After partial reduction under this condition, 14 pairs of disulfide bonds were identified (except 2 pairs in the hinge region). The specific information is shown in Table 10. Due to the symmetrical structure, a total of 7 pairs are listed. Sequence matching was performed on the map. After condition screening, the coverage of both light and heavy chains can reach more than 98%. Figure 6 The peak time of each peptide detected in Figure 5 The summary table of the peptide map sequence coverage of bevacizumab after trypsin and V8 protease digestion is shown in Table 11.

[0148] Table 10 Disulfide bond matching results of bevacizumab after trypsin and V8 protease digestion Disulfide bond peptide peak area at different reaction concentrations

[0149]

[0150]

[0151] Table 11 Summary of peptide map sequence coverage of bevacizumab after trypsin and V8 protease digestion

[0152] Attribution Number of mass peaks detected Mass spectrum peak area Sequence coverage Abundance 1: Light chain 174 3.0% 98.6% 2.59% 2: Heavy chain 502 97.0% 98.5% 97.41%

[0153] The sequence information and disulfide bond positions of SEQ ID NO:50 and SEQ ID NO:51 are as follows Fig.14 Finally, the above specific implementation method is only used to illustrate the technical solution of the present invention, but not to limit it.

Claims

1. A method for online simultaneous characterization of protein disulfide bonds and sequence information, It is characterized in that Based on the HCD mode, the protein sample is partially reduced with the reducing agent through an online derivatization system before analysis.

2. The method according to claim 1, It is characterized in that The method satisfies one or more of the following conditions: The online derivatization system uses a liquid phase autosampler, such as a U3000 liquid phase autosampler; The protein is an antibody, preferably a monoclonal antibody, for example, a complete monoclonal antibody or a Fab fragment monoclonal antibody; The reducing agent is DTT or TCEP; Preferably, the monoclonal antibody is bevacizumab or ranibizumab; More preferably, the sample aspiration speed of the online derivatization system is 0.2 to 5 μL / s, and / or the number of mixing times is 2 to 10 times.

3. The method according to claim 1, It is characterized in that The method The method comprises the following steps: one or more of protein denaturation, replacement of buffer solution, enzymatic hydrolysis, injection, detection and data analysis; preferably, the protein denaturation also includes alkylation.

4. The method according to claim 3, It is characterized in that The enzymatic hydrolysis includes single-enzyme enzymatic hydrolysis or multi-enzyme enzymatic hydrolysis; preferably, the single enzyme is trypsin, and / or the multi-enzyme enzymatic hydrolysis is double-enzyme enzymatic hydrolysis; more preferably, the double-enzyme enzymatic hydrolysis is trypsin and V8 protease, or trypsin and chymotrypsin.

5. The method according to claim 1, It is characterized in that The final concentration of the reducing agent is 1 to 100 mM, preferably 2.5 to 50 mM, more preferably 2.5 to 40 mM, and even more preferably 20 mM.

6. The method according to claim 1, It is characterized in that The reaction time of the reducing agent is 1 to 30 minutes, preferably 3 to 10 minutes.

7. The method according to claim 3, It is characterized in that The protein denaturation uses a protein denaturing agent such as urea or guanidine hydrochloride, and the alkylation uses a blocking agent that can block the end of the free thiol group such as iodoacetamide, N-ethylmaleimide or iodoacetic acid; Preferably, the final concentration of the protein denaturing agent is 1 to 25 M, and / or The final concentration of the blocking reagent is 1 to 1000 mM; More preferably, the final concentration of the protein denaturing agent is 5 to 15 M. The final concentration of the blocking reagent is 10-100 mM; Further more preferably, the final concentration of the protein denaturing agent is 6 to 8 M, The final concentration of the blocking reagent was 25 mM.

8. The method according to claim 3, It is characterized in that The replacement buffer solution uses Tris buffer or NH 4 HCO 3 Buffer; preferably, the working concentration of the replacement buffer is 10-200 mM; more preferably, the working concentration of the replacement buffer is 25-100 mM; further more preferably, the working concentration of the replacement buffer is 50 mM.

9. The method according to claim 3, It is characterized in that The detection is performed using LC-ESI-Q Exactive HF-XMS; preferably, the detection uses gradient elution, and the phase A and phase B used in the gradient elution are 0.05-0.2% formic acid and 0.05-0.2% formic acid acetonitrile, respectively. More preferably, the flow rate of the gradient elution is 0.1 to 1 mL / min, and / or, The conditions of the gradient elution are: 2% B phase 0.5-1.5 mL, 2-38% B phase 20-30 mL, 38-90% B phase 0.75-2 mL, 90% B phase 0.75-2 mL, 90%-1% B phase 0.25-1 mL, 2% B phase 0.5-1.5 mL.

10. The method according to claim 9, It is characterized in that The phase A and phase B used in the gradient elution were 0.1% formic acid and 0.1% formic acid acetonitrile, respectively. The flow rate of the gradient elution is 0.25 mL / min; The conditions of the gradient elution are: 2% B phase 0.75 mL, 2-38% B phase 24.25 mL, 38-90% B phase 1.25 mL, 90% B phase 1.25 mL, 90%-1% B phase 0.25 mL, 2% B phase 1 mL.